Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b) A multicentric retrospective analysis by Goupy, Flora et al.
HAL Id: hal-02049134
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02049134
Submitted on 4 Sep 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Intensity-modulated radiotherapy for prostate cancer
with seminal vesicle involvement (T3b) A multicentric
retrospective analysis
Flora Goupy, Stephane Supiot, David Pasquier, Igor Latorzeff, Ulrike Schick,
Erik Monpetit, Geoffrey Martinage, Chloe Herve, Bernadette Le Proust, Joël
Castelli, et al.
To cite this version:
Flora Goupy, Stephane Supiot, David Pasquier, Igor Latorzeff, Ulrike Schick, et al.. Intensity-
modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b) A multicentric
retrospective analysis. PLoS ONE, Public Library of Science, 2019, 14 (1), pp.e0210514. ￿10.1371/jour-
nal.pone.0210514￿. ￿hal-02049134￿
RESEARCH ARTICLE
Intensity-modulated radiotherapy for
prostate cancer with seminal vesicle
involvement (T3b): A multicentric
retrospective analysis
Flora Goupy1, Ste´phane Supiot2, David Pasquier3, Igor Latorzeff4, Ulrike Schick5,
Erik Monpetit6, Geoffrey Martinage3, Chloe´ Herve´1, Bernadette Le Proust7, Joel Castelli1,8,
Renaud de CrevoisierID1,8*
1 Radiation Department, CLCC Eugène Marquis,Rennes, France, 2 Radiation Department, CLCC Rene´
Gauducheau, Nantes, France, 3 Radiation Department, CLCC Oscar Lambret, Lille, France, 4 Radiation
Department, Clinique Pasteur, Toulouse, France, 5 Radiation Department, University Hospital Cavale
Blanche, Brest, France, 6 Radiation Department, Clinique Saint-Yves, Vannes, France, 7 Medical Imaging
Department, CLCC Eugène Marquis, Rennes, France, 8 University Rennes 1, LTSI (Laboratoire Traitement
du Signal et de l’Image), Inserm U1099, Rennes, France
* r.de-crevoisier@rennes.unicancer.fr
Abstract
Objectives
No study has reported clinical results of external-beam radiotherapy specifically for T3b
prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV)
while respecting the dose constraints in the organs at risk is thus so far not clearly demon-
strated. The objective of the study was to analyze the dose distribution and the clinical out-
come in a large series of patients who received IMRT for T3b prostate cancer.
Materials and methods
This retrospective analysis included all patients who received IMRT and androgen depriva-
tion therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with
available MRI images and dosimetric data.
Results
A total of 276 T3b patients were included. The median follow-up was 26 months. The
median (range) prescribed doses (Gy) to the prostate and to the ISV were 77 (70–80) and
76 (46–80), respectively. The dose constraint recommendations were exceeded in less than
12% of patients for the rectum and the bladder. The 5-year risks of biochemical and clinical
recurrences and cancer-specific death were 24.8%, 21.7%, and 10.3%, respectively. The 5-
year risks of local, pelvic lymph node, and metastatic recurrences were 6.4%, 11.3%, and
15%, respectively. The number of involved lymph nodes (� 2 or� 3) on MRI was the only
significant prognostic factor in clinical recurrence (HR 9.86) and death (HR 2.78). Grade� 2
acute and 5-year late toxicity rates were 13.2% and 12% for digestive toxicity, and 34% and
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31.5% for urinary toxicity, respectively. The dose to the pelvic lymph node and the age were
predictive of late digestive toxicity.
Conclusion
IMRT for T3b prostate cancer allows delivery of a curative dose in the ISV, with a moderate
digestive toxicity but a higher urinary toxicity. Lymph node involvement increases the risk of
recurrence and death.
Introduction
T3b prostate cancer (PCa) stage is defined as cancer invasion of one or both seminal vesicles
(SV) [1]. Even if the T staging of the D’Amico risk group classification [2] is based on digital
rectal examination (DRE), MRI is recognized as the most accurate modality to stage PCa.
Indeed, if MRI has a low sensitivity to detect the involved SV (ISV) (around 60%), its specific-
ity is particularly high (around 95%) [3]. The prediction of ISV, confirmed by surgery, is thus
statistically increased by adding MRI to clinically based models such as Partin tables or
CAPRA score [4,5]. On MRI, the incidence of T3b stage is reported to be around 10% [6,7].
After radical prostatectomy, pathological ISV ranged from 5% to 18%, depending on patient
selection [8–15].
The standard of care for locally advanced PCa is radiotherapy (RT) combined with 2 to 3
years of androgen deprivation therapy (ADT) [16,17]. The increasing number of T3b PCa
cases, due to the recent generalization of multiparametric MRI, raises, however, the issues of
both the radiation technique and its clinical results for these specific diseases. Indeed, deliver-
ing a high curative dose in the ISV [18] is particularly challenging for respecting the dose con-
straints in the rectum and bladder [19–23]. In this context, IMRT is a particularly relevant tool
to optimize the dose distribution [24,25]. To our knowledge, no study has reported clinical
results of external-beam RT and, in particular, IMRT specifically for T3b cancer. The possibil-
ity of escalating the dose to the ISV while respecting the dose constraints in the organs at risk
(OAR) is thus so far not clearly demonstrated.
The objectives of this study were, in cases of IMRT for T3b PCa, to analyze retrospectively
the planned dose to the ISV and the OARs and the patient outcome in a large series of
patients.
Patients and methods
Inclusion criteria, initial staging, treatment, and follow-up
Our retrospective analysis included all patients with T3b N0-1 M0 prostate adenocarcinoma
who received IMRT at a curative dose (� 70 Gy) in combination with ADT, in six French
institutions (Rennes, Nantes, Lille, Toulouse, Brest, and Vannes) between 2008 and 2017, with
available MRI images and dosimetric and clinical data. Only patients with ISV on pre-thera-
peutic MRI were included. All patients had prostate biopsy showing adenocarcinoma. SV
biopsy was performed in a subset of patients only, depending on the urologists. The initial
staging comprised digital rectal examination (DRE), PSA measurements, Gleason score, pelvic
MRI, and Tc99m bone scintigraphy.
The multiparametric MRI included T1- and T2-weighted (T1- and T2-WI), diffusion-
weighted imaging (DWI), and dynamic, contrast-enhanced imaging with a 1.5 Tesla magnet
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without endorectal coil. ISV was defined on T2–WI images as SV disruption or loss of the nor-
mal architecture, focal or diffuse areas of low signal intensity, low signal intensity causing a
mass effect, or evident tumor at the prostate base extending to the SV. ISV was defined on
DWI images as low focal signal lesions, relative to benign prostate tissues on apparent diffu-
sion coefficient maps, within the SV. ISV was defined on dynamic T1–WI as symmetric or
irregular SV wall enhancement ISV [26]. The length of ISV was defined on MRI, considering
the three thirds of SV in the cranio-spinal axis. Finally, the lymph node involvement (N1) was
defined as a pelvic node� 8 mm in the smallest diameter [27]. Approximately 50% of MRI
images were subjected to a second independent reading by an expert radiologist.
Patients underwent simulation and treatment in the supine position. Intravenous iodine
contrast was required. At the time of simulation, there were no recommendations concerning
bowel or bladder filling. During treatment, patients had to keep a full bladder. The target vol-
ume and organs at risk were delineated on CT slices, whose spacing was 2 or 3 mm. The target
delineation and dose distribution were performed according to the French Study Group on
Urogenital Tumors (GETUG) guidelines [21]. The clinical target volume (CTV) included sys-
tematically the whole prostate and the non-involved SV and ISV. The SV were therefore
divided in three equal thirds, according to the cranio-spinal axis. The prophylactic irradiation
of the pelvic lymph nodes, performed in 90% of cases, depended on the choice of the radiation
oncologist. The pelvic lymph nodes were systematically irradiated in case of involvement of
the pelvic lymph nodes at MRI. The pelvic lymph node CTV included the obturator, presacral,
external, internal and common iliac lymph nodes. The planning target volume (PTV) margins
were defined as 5 to 10 mm around the prostate and SV, except in the posterior direction,
where the margin was limited to 5 mm, and 7 mm around the pelvic lymph node. The total
dose delivered to the prostate (PTV) ranged from 70 to 80 Gy at a standard fractionation of 2
Gy/fr during 7 to 8 weeks, in 87% of patients. In one center (13% of the patients), the prostate
total dose was 74.8 Gy, at a fractionation of 2.2 Gy/fr in 6.8 weeks using a simultaneous inte-
grated boost (SIB) technique. The total dose to the non-involved SV and ISV had range from
46 to 80 Gy, depending on the choice of the radiation oncologist. The prophylactic total dose
to the pelvis ranged from 46 to 50 Gy at 2 Gy/fr in 87% of patients. This total dose was 54.4 Gy
at 1.6 Gy/fr in 13% of patients, using the SIB technique. A boost could be delivered to the
involved lymph nodes (at MRI) up to 74 Gy, depending also on the radiation oncologist. The
rectal wall was generated with a thickness of 5 mm from the external, manually delineated rec-
tal contour. The rectal length was defined as 1 cm from both sides of the prostate and SV PTV.
The bladder wall was generated with a thickness of 7 mm from the external, manually delin-
eated bladder contour. The dose volume histogram had to respect the GETUG recommenda-
tions [21] for the rectum (V60 Gy< 50%, V72< 25%, maximum dose < 76 Gy), for the
bladder (V60 Gy < 50%, V70 < 50%, maximum dose< 80 Gy), and for the femoral heads
(V55 < 5%). IMRT could use 6 to 23 MV X-ray beams.
The follow-up consisted of clinical assessments and PSA measurements repeated every 6
months. Imaging (pelvic MRI, thoraco-abdominal computed tomography and bone scintigra-
phy) was performed in cases of biochemical progression or suspicion of clinical recurrence.
Endpoints and statistical analysis
The dosimetric charts were analyzed to report the doses delivered toward the PTV and to the
CTV of the prostate, uninvolved SV, and ISV (considering each third of the SV), and unin-
volved and involved pelvic lymph nodes. The doses to the rectum and bladder were reported
according to the reference points of the GETUG [21], RTOG [22], and QUANTEC [20]. Pear-
son correlation coefficients (r) were calculated to search for correlation between the doses to
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the OARs and target volume parameters (volume, length of the ISV, or doses). Significant cor-
relations with r> 0.5 only were reported.
The follow-up was defined as the time between the first day of RT and the latest news. Fol-
low-up was calculated using reverse Kaplan-Meier estimation. Biochemical recurrence was
defined as a PSA level equal to or greater than the PSA nadir plus 2 ng/mL or the initiation of
salvage androgen deprivation therapy (ADT) [28]. Clinical recurrence was defined by local
recurrence, pelvic lymph node recurrence, or metastasis. Disease-free survival (DFS) was
defined as the time between the first day of RT and one of the first following events, when
occurring: biochemical recurrence, clinical recurrence, or death.
Acute and late digestive and urinary toxicities were retrospectively scored in accordance
with the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The toxic-
ities were acute when they occurred within 90 days after the start of RT and late otherwise.
Kaplan-Meier analysis was used to calculate the risk of recurrences, deaths, and late urinary
or digestive toxicity (grade� 2). A logistic regression test was used to identify predictors of
acute toxicity in univariate and multivariate analyses. Univariate and multivariate Cox regres-
sion analyses were performed to identify predictors of recurrences, deaths, and late toxicity.
Significant parameters (defined as p value� 0.05) identified in univariate analyses were tested
in multivariate analyses. The predictive performance of the models was estimated by the area
under the receiver operating characteristic (ROC) curve (AUC) for the logistic regression
model and by the C-index for the Cox model. The following parameters were tested for recur-
rences and survivals: treatment center; age; T stage at DRE; PSA; number of D’Amico risk fac-
tors; MRI parameters such as extracapsular extension, bilateral prostate, or SV involvements;
proximal ISV only; whole ISV; number of segment ISV; pelvic lymph node involvement; num-
ber of involved lymph nodes (on MRI); pathological parameters such as Gleason score, num-
ber of positive biopsies in the prostate, positive biopsies in SV when performed; dosimetric
parameters such as the doses prescribed to the target volumes; and ADT duration. The follow-
ing parameters were tested for toxicity: treatment center; age; arterial hypertension; cardiovas-
cular disease; diabetes; anticoagulant treatment; history of pelvic surgery; T stage at DRE; MRI
parameters such as bilateral SV involvement, proximal ISV only; whole ISV; number of seg-
ment ISV, and pelvic lymph node involvement; dosimetric parameters such as the doses pre-
scribed to the target volumes and to the OARs; and ADT duration. Analyses were performed
in the whole series and considering only the patients without pathological pelvic lymph nodes
at MRI.
Statistical analyses were performed using the Statistical Package for the Social Sciences
(SPSS) version 20.0 (IBM Corp., Armonk, NY, USA), and R version 3.4.3 (GNU Project,
Lucent Technologies).
The research has been approved by the institutional review board of the Eugene Marquis
Cancer Center.
Results
Patients, tumor and treatment characteristics
Our screening found 12% of T3b patients among all the irradiated patients for localized PCa at
a curative intent (� 70 Gy). Among a total of 309 patients identified as having received EBRT
at a curative intent for T3b PCa, 30 patients were excluded because of having been treated by
three-dimensional conformal radiotherapy (3D-CRT) technique and 3 patients because the
dosimetric chart was not available. A total of 276 patients were finally included. Patients and
tumor characteristics are detailed in Table 1. Details are provided regarding MRI tumor
characteristics.
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Table 1. Patient and tumor characteristics.
PATIENTS CHARACTERISTICS
Age (years) � 69 (42–86)
Comorbidities (%)
Arterial hypertension 41
Cardiovascular disease 23
Diabetes 13
Anticoagulant treatment 29
History of pelvic surgery 31
D’AMICO TUMOR CHARACTERISTICS
PSA (ng/mL) � 27 (2–217)
T Stage at DRE (%)
T1 11
T2 35
T3 54
Gleason score (%)
� 6 7
7 (3+4) 27
7 (4+3) 24
8 24
9–10 18
Number of D’Amico high risk factor (%)
One (T3 only) 21
Two 65
Three 14
BIOPSY CHARACTERISTICS
Number of biopsies in the prostate � 12 (2–24)
Number of positive biopsies in the prostate � 8 (1–21)
Patients with SV biopsies (%) 8
Patients with positive SV biopsies when SV biopsy was performed (%) 86
MRI TUMOR CHARACTERISTICS (%)
Extracapsular extension 73
Bilateral prostate involvement 68
Bilateral involved SV 41
Length of involved SV
Proximal 1/3 only 64
Proximal 2/3 only 20
Entire SV 16
LYMPH NODE INVOLVEMENT˚
Number of patients (%) 26
Number of involved node per patient � 3 (1–16)
Bilateral involvement (%) 48
Localization (%)
Pararectal 14
Presacral 10
Obturator 29
Intern iliac 45
Extern iliac 43
Common iliac 20
�Mean value (range). DRE: digital rectal examination; SV: seminal vesicle;˚ defined as pelvic node� 8 mm in the
smallest diameter on MRI.
https://doi.org/10.1371/journal.pone.0210514.t001
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The median (range) prescribed doses (Gy) were 77 (70–80) for the prostate, 50 (46–80) for
the uninvolved SV (on MRI), 76 (46–80) for the ISV, 50 (46–55) for the uninvolved pelvic
lymph nodes, and 52 (46–74) for the involved lymph nodes (on MRI). The prescribed doses to
the uninvolved SV and ISV were equal to or greater than 70 Gy for 22% and 64% of patients,
respectively. The pelvic lymph nodes without lymph node involvement were treated at a pro-
phylactic dose in 90% of cases. The mean radiotherapy duration was 56 days (range: 14–77).
The IMRT technique was based on the use of a five-field beam in 30% of patients, volumet-
ric-modulated arc therapy in 45%, and tomotherapy in 25%. Image-guided radiotherapy
(IGRT) for prostate was used in 71% of patients.
The dosimetric characteristics of the prostate, the ISV, and uninvolved SV by each third of
the SV appear in Fig 1 and Table 2. The dosimetric characteristics for the rectum and the blad-
der appear in Table 3. The rectum V72 was correlated with the prostate PTV D95 (r = 0.53,
p< 0.01). The percentage of cases not respecting the dose constraints for the rectum and the
bladder also appear in Table 3, ranging from 0% to 12% of patients, depending on the OAR
and the recommendation.
The mean duration of ADT was 36 months.
Carcinological results and prognostic analysis
The median and mean follow-up were 26 and 36 months (95% CI: 33–39 months),
respectively.
Five-year biochemical and clinical recurrence rates were 24.8% (95% CI: 15.0–34.6%) and
21.7% (95% CI: 12.5–30.9%), respectively (Fig 2A). Regarding clinical recurrence, 5-year local,
pelvic lymph node, and metastatic recurrence rates were 6.4% (95% CI: 0.6–12.2%), 11.3%
(95% CI: 3.7–18.9%), and 15% (95% CI: 7.8–22.2%), respectively (Fig 2B). Five-year DFS,
cause-specific survival, and overall survival rates were 65.8% (95% CI: 55.6–76.0%), 89.7%
(95% CI: 82.9–96.5%) and 78.8% (95% CI: 70.2–87.4%), respectively (Fig 2A).
Fig 1. Dosimetric characteristics of each third of the seminal vesicle, depending on the length of involved seminal vesicles on MRI. Mean value (range) in Gy; Dx:
dose delivered to x% of volume; PTV: planning target volume; CTV: clinical target volume; SV: seminal vesicle; SV PTV = SV CTV + 5 mm in all directions. Each SV
was divided in three equal thirds, according to the cranio-spinal axis. The mean dose for each third of both SV is represented. The proximal third of the seminal vesicle is
in orange, the second third is in green, and the distal third is in blue. The involved part of the seminal vesicle is in black.
https://doi.org/10.1371/journal.pone.0210514.g001
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Considering the whole series, Table 4 presents the results of univariate analysis testing the
impact of all parameters on each carcinological endpoint. Lymph node involvement on MRI
increased significantly all the risks of recurrences (biochemical, clinical, local, lymph node and
metastases) and deaths (Pca and overall) in univariate analysis (Table 4). Extracapsular exten-
sion, high number of prostate positive biopsies or ISV segments at MRI and high Gleason sore
increased significantly the risk of overall or PCa specific death. Table 5 details the results of
multivariate analysis. The number of involved pelvic lymph nodes� 3 on MRI remained the
only significant prognostic factor increasing the risk of occurrence of all carcinological end-
points, except overall death, with hazard ratios (HR) ranging from 5.3 to 12.9, and C-index
ranging from 0.60 to 0.70. Fig 3 illustrates the impact of lymph node involvement (� 2 or� 3
lymph nodes on MRI) on the endpoints. For overall death, the number of prostate positive
biopsies remained the only significant factor (C-index = 0.71).
Considering only the patients without lymph node involvement on MRI, the high number
of D’Amico risk factors or ISV segments on MRI or pathological positive prostate biopsies and
extracapsular extension on MRI increased significantly the risk of death in univariate analysis
(Table 6). In multivariate analysis, only the high number of prostate positive biopsies increased
significantly the risk of death (HR = 1.18; C-index = 0.77) (Table 5). A high Gleason score
increased at the limit of significance the risk of PCa specific death (HR = 3.34, p = 0.056; C-
index = 0.81).
Urinary and digestive toxicity rates and predictors of toxicity
Acute urinary toxicity rates were 66% for grades 0–1, 31.4% for grade 2, and 2.6% for grade 3.
One patient stopped the radiotherapy course because of grade 3 urinary toxicity. Five-year late
urinary grade� 2 toxicity rate was 31.5% (95% CI: 23.3–39.7). Five patients (1.8%) presented
late urinary grade 3 toxicity, and none had grade 4 toxicity.
Considering the whole series, Table 7 details the results of univariate analysis testing the
impact of all parameters on urinary grade� 2 toxicity. The only significant predictive factors
on acute and late toxicity were history of cardiovascular disease (HR = 2.45; AUC = 0.57) and
Table 2. Doses to the prostate and the seminal vesicles, depending on the length of seminal vesicle involvement
on MRI.
PROSTATE
PTV D95 74 (70–76)
CTV D99 75 (70–80)
INVOLVED SEMINAL VESICLES
Part(s) of ISV PTV D95 CTV D99
If involvement limited at proximal 1/3 73 (58–79) 74 (54–80)
If involvement limited at proximal 2/3 74 (63–77) 75 (65–78)
If involvement in the entire SV 67 (54–72) 69 (55–78)
Whatever the involved part of ISV 72 (53–79) 73 (54–80)
NOT INVOLVED SEMINAL VESICLES
Part(s) of non-involved SV PTV D95 CTV D99
If non-involvement of the distal 2/3 63 (49–77) 65 (50–78)
If non-involvement of the distal 1/3 63 (51–76) 68 (53–77)
Whatever the non-involved part of SV 63 (49–77) 66 (50–78)
Mean value (range) in Gy. Dx: dose delivered to x% of the target volume; PTV: planning target volume; CTV: clinical
target volume; ISV: involved seminal vesicles on MRI.
https://doi.org/10.1371/journal.pone.0210514.t002
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ADT duration (HR = 0.98; AUC = 0.55), respectively. Considering only the patients without
lymph node involvement on MRI, the same significant predictive factors were found (Table 8).
Acute digestive toxicity rates were 86.8% for grades 0–1, 11% for grade 2, and 2.2% for
grade 3. Five-year late digestive grade� 2 toxicity rate was 12% (95% CI: 6.8–17.2%). Five
patients (1.8%) presented late digestive grade 3 toxicity and none had grade 4 toxicity.
Considering the whole series, Table 7 details univariate analysis testing the impact of all
parameters on digestive grade� 2 toxicity. The only significant predictive factor on acute tox-
icity was the non-involved SV dose (HR = 1.09; AUC = 0.73). The significant predictive factors
on late digestive toxicity were age (HR = 1.08), arterial hypertension (HR = 2.87), proximal
ISV only on MRI (HR = 0.42) and non-involved pelvic lymph node dose (HR = 1.11). Table 9
details the results of multivariate analysis. The retained significant predictive factors on late
digestive toxicity were age (HR 1.09) and pelvic lymph node dose (HR = 1.12) with an AUC of
0.78. Fig 4 illustrates the impact of pelvic node dose on late digestive toxicity (grade� 2). Con-
sidering only the patients without lymph node involvement on MRI, univariate analysis
retained the same significant predictive factors except the proximal ISV only (Table 8). In mul-
tivariate analysis, the significant predictive factors were age, arterial hypertension and pelvic
lymph node dose with an AUC of 0.84 (Table 9).
Discussion
This study is the only one reporting experience of IMRT for specifically T3b PCa. Escalating
the dose in the ISV potentially exposes the patient to an increased risk of toxicity. In our study,
IMRT allowed dose escalation in ISV while respecting the dose constraints for the OARs in
more than 85% of cases. The dose to the ISV depended, however, on the involved third of the
Table 3. Dosimetric characteristics of the rectum and the bladder according to the recommendations of the cooperative groups.
Vx MEAN VALUES AND % OF PATIENTS OVER THE THREHOLD Vx VALUE RECTUM BLADDER
V50 Mean value (range) (Gy) 37 (10–94) 38 (6–96)
% of patients with V50� 50% & 10 -
V60 Mean value (range) (Gy) 23 (5–61) 26 (2–71)
% of patients with V60� 50%˚# 0 7
% of patients with V60� 35% & 6 -
V65 Mean value (range) (Gy) 18 (3–47) 21 (2–60)
% of patients with V65� 50% #& - 5
% of patients with V65� 35% # 1 -
% of patients with V65� 25% & 12 -
V70 Mean value (range) (Gy) 12 (1–27) 16 (0–51)
% of patients with V70� 50%˚ - 0
% of patients with V70� 35% #& - 6
% of patients with V70� 20% #& 8 -
V72 Mean value (range) (Gy) 9 (0–22) -
% of patients with V72� 25%˚ 0 -
V75 Mean value (range) (Gy) 3 (0–14) 9 (0–40)
% of patients with V75� 25% #& - 5
% of patients with V75� 15% #& 0 -
% of patients with V75� 5% [23] 21 -
Vx: Dose–volume threshold recommendations (volume of organ receiving at least x Gy in %) according to the GETUG (˚) (21); RTOG (#) [22]; QUANTEC (&) [20] or
Fiorino et al.[23].
https://doi.org/10.1371/journal.pone.0210514.t003
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Fig 2. Carcinological results for T3b prostate cancer patients. (A)Results for biochemical and clinical recurrences and deaths. (B) Results for clinical recurrence
detailed by local recurrence as the first event (local, pelvic lymph node, and metastasis). Clinical recurrence was defined as at least local or pelvic lymph node or
metastasis recurrence.
https://doi.org/10.1371/journal.pone.0210514.g002
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Table 4. Univariate analysis testing the impact of all parameters on all carcinological endpoints in the whole series.
Parameters Biochemical
recurrence
Clinical
recurrence�
Local
recurrence
Pelvic lymph
node
recurrence
Metastasis
recurrence
Overall death PCa specific
death
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR (95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
Center parameter 0.24 0.60 0.77 0.49 0.85 0.86 0.90
Clinical
parameter
Age 0.11 0.054 0.79 0.67 0.10 0.07 0.74
Tumor
parameters
T stage at DRE 0.90 0.64 0.63 0.96 0.63 0.62 0.41
PSA 0.78 0.98 0.
38
0.22 0.95 0.51 0.49
Number of D’Amico
risk factors
0.59 0.40 0.48 0.43 0.81 0.51 0.09
MRI
parameters
Extracapsular
extension
0.08 0.07 0.93 0.44 0.10 0.034 4.74
(1.13–
20.00)
0.23
Bilateral prostate
involvement
0.94 0.99 0.76 0.33 0.38 0.32 0.49
Bilateral SV
involvement
0.08 0.08 0.39 0.41 0.13 0.08 0.07
Proximal ISV only
(at least one SV)
0.72 0.93 0.14 0.17 0.73 0.66 0.21
Whole ISV
(at least one SV)
0.73 0.97 0.62 0.86 0.75 0.19 0.13
Number of ISV
segments #
0.84 0.49 0.73 0.98 0.42 0.031 1.30
(1.02–
1.64)
0.06
Pelvic lymph node
involvement
0.002 2.94
(1.47–
5.87)
0.005 2.90
(1.38–
6.03)
0.85 0.39 0.001 4.70
(1.95–
11.36)
0.39 0.017 4.45
(1.30–
15.23)
Number of involved
lymph nodes
<0.001 1.44
(1.24–
1.67)
<0.001 1.47
(1.26–
1.71)
0.43 0.014 1.38
(1.01–
1.80)
<0.001 1.50
(1.30–
1.76)
0.19 0.001 1.45
(1.16–
1.81)
Number of involved
lymph nodes (�3)
<0.001 8.20
(3.68–
18.26)
<0.001 9.86
(4.28–
22.69)
0.04 5.41
(1.06–
27.47)
0.012 5.3
(1.43–
19.6)
<0.001 12.95
(5.21–
32.17)
0.038 2.78
(1.06–
7.29)
0.001 7.60
(2.22–
26.03)
Pathological
parameters
Gleason score 0.28 0.12 0.31 0.27 0.19 0.14 0.020 2.33
(1.15–
4.74)
Number of positive
biopsies in the
prostate
0.60 0.32 0.89 0.68 0.18 0.003 1.18
(1.06–
1.31)
0.08
Positive biopsies in
SV˚
0.26 0.28 0.58 0.49 0.37 0.92 0.53
(Continued)
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Table 4. (Continued)
Parameters Biochemical
recurrence
Clinical
recurrence�
Local
recurrence
Pelvic lymph
node
recurrence
Metastasis
recurrence
Overall death PCa specific
death
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR (95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
Dosimetric
parameters
Dose prescribed to
prostate
0.43 0.50 0.83 0.99 0.37 0.92 0.40
Dose prescribed to
ISV
0.89 0.70 0.81 0.35 0.54 0.50 0.18
Dose prescribed to
non-involved SV
0.74 0.94 0.18 0.30 0.23 0.18 0.33
Dose prescribed to
non-involved pelvic
lymph node
0.65 0.75 0.18 0.22 0.23 0.17 0.19
Dose prescribed to
involved pelvic
lymph node
0.64 0.60 0.95 0.48 0.64 0.66 0.34
Systemic
treatment
parameter
ADT duration 0.18 0.10 0.86 0.003 1.04
(1.01–
1.06)
0.40 0.10 0.21
PCa: prostate cancer; DRE: digital rectal examination; SV: seminal vesicle; ISV: involved SV; ADT: androgen deprivation therapy. Each SV was divided in three equal
segment in the cranio-spinal axis.
�Clinical recurrence was defined as at least local or pelvic lymph node or metastasis recurrence.
# The number of ISV could range from 1 (one proximal third of one ISV) to 6 (two whole ISV).
˚Only 8% of patients had biopsy of the SV. The Cox model has been used. For significant p-values (p�0.05), hazard ratios (HR) with 95% confidence intervals (CI) are
given.
https://doi.org/10.1371/journal.pone.0210514.t004
Table 5. Multivariate analysis testing the impact of all parameters on all carcinological endpoints in the whole series and for patients without lymph node involve-
ment on MRI.
Endpoints Whole series Patients without pelvic lymph node involvement
Parameters p value HR (95% CI) C-
index
Parameters p value HR (95% CI) C-
index
Biochemical recurrence Number of involved lymph
nodes (�3)
<0.001 8.20 (3.68–
18.26)
0.66 NI - - -
Clinical recurrence Number of involved lymph
nodes (�3)
<0.001 9.86 (4.28–
22.69)
0.68 NI - - -
Local recurrence Number of involved lymph
nodes (�3)
0.04 5.41 (1.06–
27.47)
0.66 NI - - -
Pelvic lymph node
recurrence
Number of involved lymph
nodes (�3)
0.012 5.30 (1.43–
19.6)
0.60 NI - - -
Metastasis recurrence Number of involved lymph
nodes (�3)
<0.001 12.95 (5.21–
32.17)
0.70 NI - - -
Overall death Number of positive biopsies in
the prostate
0.003 1.18 (1.06–
1.31)
0.71 Number of positive biopsies in
the prostate
0.018 1.18 (1.03–
1.35)
0.77
PCa specific death Number of involved lymph
nodes (�3)
0.001 7.60 (2.22–
26.03)
0.69 Gleason score 0.056� 3.34 (0.98–
11.51)
0.81
PCa: prostate cancer; NI: not identified
�Trend towards statistical significance. Clinical recurrence was defined as at least local or pelvic lymph node or metastasis recurrence. The number of involved lymph
nodes (�3) was defined on MRI. The predictive performance of the Cox model was estimated by the C-index. Hazard ratios (HR) with 95% confidence intervals (CI)
are given.
https://doi.org/10.1371/journal.pone.0210514.t005
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SV, the distal involved third of the SV receiving less dose than the proximal third of the SV
close to the prostate (Fig 1). Moreover, the uninvolved SV also received a high dose (mean
dose� 63 Gy) (Table 2), depending also on the uninvolved SV third (Fig 1). By escalating the
dose (� 76 Gy) in the prostate only with 3D-CRT, the literature shows that the 5-year urinary
and digestive grade� 2 toxicity rates range from 12% to 21% and from 7% to 21%, respectively
[19,21,29]. With IMRT, the 5-year digestive toxicity rate are reduced to less than 10% [30]. By
escalating the dose in both the prostate and the whole or a part of the SV, the toxicity appears
increased, with 5-year urinary and digestive grade� 2 toxicity rates ranging with 3D-CRT
from 12% to 39% and from 26% to 32%, respectively [31,32], and with IMRT from 12% to 16%
and from 4% to 21%, respectively [22,33]. Regarding digestive toxicity, these results by appear,
therefore, comparable to our study (5-year rate of 12%). Our rate of urinary toxicity appears,
however, quite higher (5-year rate of 31.5%), despite the systematic use of IMRT and the use of
IGRT in the majority of cases. Reducing SV PTV below 5 mm to decrease toxicity appears to
be a poor option [34]. Indeed, the SV present deformations and move independently from the
prostate, with a motion magnitude larger than the prostate, even if the tumor infiltration
within the SV reduces their mobility [35,36].
Table 10 summarizes the literature, reporting results of treatment for specifically T3b PCa.
The large majority of treatments are based on surgical experience in selected T3b PCa patients.
Our treatment results appear thus comparable to surgical series in which the 5-year biochemi-
cal DFS rate ranges from 21% to 70% (66% in our study), and the 5-year cause-specific survival
rate ranges from 94% to 98% (90% in our study) [8–13,37–41]. Such retrospective comparison
between treatments must be considered with caution due in particular to biases in patient and
tumor selections (highest age, PSA, and Gleason score in our RT series compared to the surgi-
cal studies).
The best mean for dose escalation is BT. Indeed, the superiority of the combined treatment
over EBRT has been demonstrated only in series comprising both intermediate and high-risk
PCa in terms of biochemical control in three randomized studies [42–44], of metastases, and
even of overall survival in large national databases [45]. More recently, in high-risk PCa and
after adjustment for PCa prognostic factors, other medical conditions, and socioeconomic fac-
tors, the combination of BT to EBRT or radical prostatectomy have been shown to provide
higher overall survival than EBRT combined with ADT [46]. The proportion of T3 cancer
treated by surgery was, however, small in this study. Only five studies, comprising a relatively
small number of patients (� 80), reported results of the combination of EBRT and brachyther-
apy (BT) [47–50] or the use of BT only [51] for T3b PCa. Despite technique considerations
with difficulties to ensure needles to the distal parts of SV, more than 80% of the entire SV vol-
ume received a dose escalation [48]. Furthermore, BT with dose escalation in SV compared to
BT without dose escalation in SV increased to 22% of the 3 year DFS [48]. Our treatment
results appear, therefore, slightly lower than those reported for the combined treatment, with
5-year DFS and cause-specific survival rates ranging from 70% to 82% and around 95% versus
66% and 90% in our study, respectively. However, these BT series excluded patients with
lymph node involvement at imaging.
The incidence of lymph node involvement in T3b PCa is particularly high, ranging from
12% to 38% in surgical series [8–13,37–41] and 26% in our series (on MRI). In surgical studies,
the lymph node involvement is the most significant prognostic factor of biochemical
Fig 3. Impact of lymph node involvement (� 2 or� 3 lymph nodes on MRI) on carcinological outcomes. (A)on
biochemical recurrence, (B) on clinical recurrence, (C) on death. Clinical recurrence was defined as at least local or
pelvic lymph node or metastasis recurrence. The p value has been calculated from the logrank test.
https://doi.org/10.1371/journal.pone.0210514.g003
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recurrence (HR = 2.1), DFS (HR = 2.9), and cause-specific survival (HR = 2.4) [9,14]. The
lymph node involvement was also identified in our study as the only significant prognostic fac-
tor in multivariate analysis on biochemical recurrence (HR = 2.9), clinical recurrence
Table 6. Univariate analysis testing the impact of all parameters on carcinological endpoints for patients without lymph node involvement on MRI.
Parameters Biochemical
recurrence
Clinical
recurrence�
Local
recurrence
Pelvic lymph
node
recurrence
Metastasis
recurrence
Overall death PCa specific
death
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR
(95%
CI)
p HR (95%
CI)
p HR
(95%
CI)
Center parameter 0.11 0.30 0.92 0.94 0.23 0.88 0.97
Clinical parameter Age 0.37 0.28 0.65 0.99 0.62 0.48 0.37
Tumor parameters T stage at DRE 0.43 0.93 0.43 0.48 0.22 0.91 0.38
PSA 0.34 0.41 0.64 0.39 0.43 0.78 0.99
Number of D’Amico
risk factors
0.98 0.44 0.37 0.71 0.64 0.046 1.90
(1.01–
3.57)
0.28
MRI parameters Extracapsular extension 0.64 0.48 0.93 0.84 0.83 0.049 7.58
(1.01–
56.80)
0.42
Bilateral prostate
involvement
0.60 0.51 0.77 0.82 0.58 0.33 0.42
Bilateral SV
involvement
0.51 0.55 0.95 0.51 0.96 0.15 0.17
Proximal ISV only
(at least one SV)
0.61 0.97 0.25 0.39 0.41 0.78 0.91
Whole ISV (at least one
SV)
0.58 0.81 0.67 0.58 0.81 0.27 0.31
Number of segment ISV
#
0.89 0.77 0.82 0.21 0.84 0.014 1.46
(1.08–
2.00)
0.33
Pathological
parameters
Gleason score 0.79 0.30 0.34 0.90 0.62 0.07 0.056
Number of positive
biopsies in the prostate
0.54 0.69 0.89 0.28 0.25 0.018 1.18
(1.03–
1.35)
0.97
Positive biopsies in the
SV˚
0.36 0.39 0.55 0.53 0.54 0.85 0.66
Dosimetric
parameters
Dose prescribed to
prostate
0.24 0.21 0.80 0.56 0.22 0.21 0.45
Dose prescribed to ISV 0.44 0.54 0.85 0.17 0.79 0.88 0.53
Dose prescribed to non-
involved SV
0.12 0.12 0.25 0.07 0.99 0.12 0.057
Dose prescribed to
pelvic lymph node
0.73 0.71 0.59 0.43 0.95 0.24 0.18
Systemic
treatment
parameter
ADT duration 0.13 0.06 0.71 0.07 0.15 0.13 0.43
PCa: prostate cancer; DRE: digital rectal examination; SV: seminal vesicle; ISV: involved SV; ADT: androgen deprivation therapy. Each SV was divided in three equal
segment in the cranio-spinal axis.
�Clinical recurrence was defined as at least local or pelvic lymph node or metastasis recurrence.
# The number of ISV could range from 1 (one proximal third of one ISV) to 6 (two whole ISV).
˚Only 8% of patients had biopsy of the SV. The Cox model has been used. For significant p-values (p�0.05), hazard ratios (HR) with 95% confidence intervals (CI) are
given.
https://doi.org/10.1371/journal.pone.0210514.t006
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(HR = 2.9), and PCa death (HR = 4.4). Moreover, a lymph node number greater than or equal
to three increased dramatically the risk of clinical recurrence (HR = 9.9) and death (HR = 2.8),
suggesting, therefore, to add another systemic treatment to this subgroup of patients such as
chemotherapy or second-generation hormone therapy. This threshold in the number of posi-
tive lymph nodes has also recently been reported to affect patient outcome after PCa
Table 7. Univariate analysis testing the impact of all parameters on grade� 2 toxicity in the whole series.
Parameters Acute grade� 2 toxicity Late grade� 2 toxicity
Urinary Digestive Urinary Digestive
p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
Center parameter 0.027 NA 0.07 0.08 0.38
Clinical parameter Age 0.73 0.85 0.47 0.016 1.08 (1.02–
1.16)
Arterial hypertension 0.65 0.30 0.68 0.018 2.87 (1.20–
6.84)
Cardiovascular disease 0.018 2.45 (1.16–
5.15)
0.23 0.79 0.83
Diabetes 0.50 0.84 0.78 0.52
Anticoagulant treatment 0.30 0.58 0.44 0.71
History of pelvic surgery 0.57 0.74 0.87 0.20
Tumor parameters T stage at DRE 0.91 0.54 0.61 0.28
MRI parameters Bilateral SV involvement 0.66 0.73 0.68 0.42
Proximal ISV only (at least one SV) 0.24 0.39 0.71 0.047 0.42 (0.17–
0.98)
Whole ISV (at least one SV) 0.99 0.22 0.79 0.51
Number of segment ISV # 0.70 0.60 0.99 0.11
Pelvic lymph node involvement 0.35 0.41 0.059 0.97
Dosimetric target volumes
parameters
Dose prescribed to prostate 0.45 0.24 0.85 0.47
Dose prescribed to ISV 0.92 0.12 0.74 0.36
Dose prescribed to non-involved SV 0.18 <0.001 1.09 (1.04–
1.13)
0.19 0.66
Dose prescribed to non-involved pelvic
lymph node
0.79 0.12 0.69 0.005 1.11 (1.03–
1.19)
Dose prescribed to involved pelvic lymph
node
0.17 0.41 0.16 0.52
Dosimetric organ at risks
parameters
Rectum V40 NA 0.85 NA 0.45
Rectum V50 NA 0.88 NA 0.93
Rectum V60 NA 0.70 NA 0.96
Rectum V65 NA 0.87 NA 0.99
Rectum V70 NA 0.85 NA 0.97
Rectum V75 NA 0.20 NA 0.14
Bladder V50 0.80 NA 0.22 NA
Bladder V60 0.98 NA 0.27 NA
Bladder V70 0.82 NA 0.40 NA
Systemic treatment parameter ADT duration 0.12 0.68 0.016 0.98 (0.96–
0.99)
0.57
DRE: digital rectal examination; SV: seminal vesicle; ISV: involved SV; Vx: volume of organ receiving at least x Gy in %; ADT: androgen deprivation therapy; NA: not
applicable. Each SV has been divided in three segments in the cranio-spinal axis.
# The number of ISV could range from 1 (one proximal third of on ISV only) to 6 (two whole ISV). The logistic regression test has been used for acute toxicity. The Cox
model has been used for late toxicity. For significant p-values (p�0.05), hazard ratios (HR) with 95% confidence intervals (CI) are given.
https://doi.org/10.1371/journal.pone.0210514.t007
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radiotherapy [52]. Moreover, the benefit of radiotherapy can also be discussed for patients
with positive lymph nodes. Indeed, even if there is a lack of randomized evidence, retrospective
studies suggest that radiotherapy may improve survival for the subgroup of patients [53–57].
Furthermore, among men with pN1 PCa (at radical prostatectomy), the subgroup benefiting
from radiotherapy is the one with one to two positive nodes, pathological Gleason score 7–10,
and pT3b/4 disease or positive surgical margins [58].
Other poor prognosis factors, such as a high Gleason score (� 8), high tumor infiltration
on prostate biopsy and extracapsular extension were also identified as poor prognostic factors
in several surgical and BT series [8,10,14,49,59], as well as in our series in univariate analysis.
Table 8. Univariate analysis testing the impact of all parameters on grade� 2 toxicity for patients without lymph node involvement on MRI.
Parameters Acute grade� 2 toxicity Late grade� 2 toxicity
Urinary Digestive Urinary Digestive
p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
Center parameter 0.21 0.59 0.26 0.73
Clinical parameter Age 0.92 0.54 0.54 0.004 1.13 (1.04–
1.23)
Arterial hypertension 0.69 0.13 0.92 0.007 4.84 (1.55–
15.11)
Cardiovascular disease 0.035 2.33 (1.06–
5.13)
0.34 0.96 0.92
Diabetes 0.69 0.34 0.92 0.68
Anticoagulant treatment 0.33 0.33 0.42 0.37
History of pelvic surgery 0.68 0.66 0.81 0.68
Tumor parameters T stage at DRE 0.42 0.47 0.89 0.37
MRI parameters Bilateral SV involvement 0.90 0.30 0.67 0.59
Proximal ISV only (at least one
SV)
0.20 0.83 0.63 0.22
Whole ISV (at least one SV) 0.69 0.52 0.29 0.29
Number of segment ISV # 0.61 0.49 0.31 0.92
Dosimetric target volumes
parameters
Dose prescribed to prostate 0.49 0.07 0.50 0.43
Dose prescribed to ISV 0.97 0.25 0.75 0.86
Dose prescribed to non-involved
SV
0.12 0.018 1.06 (1.01–
1.12)
0.52 0.32
Dose prescribed to pelvic lymph
node
0.95 0.15 0.76 0.007 1.25 (1.06–
1.47)
Dosimetric organ at risks
parameters
Rectum V40 NA 0.57 NA 0.86
Rectum V50 NA 0.76 NA 0.74
Rectum V60 NA 0.94 NA 0.87
Rectum V65 NA 0.96 NA 0.82
Rectum V70 NA 0.87 NA 0.84
Rectum V75 NA 0.23 NA 0.47
Bladder V50 0.76 NA 0.40 NA
Bladder V60 0.95 NA 0.09 NA
Bladder V70 0.97 NA 0.11 NA
Systemic treatment parameter ADT duration 0.21 0.73 0.013 0.97 (0.96–
0.99)
0.56
DRE: digital rectal examination; SV: seminal vesicle; ISV: involved SV; Vx: volume of organ receiving at least x Gy in %; ADT: androgen deprivation therapy; NA: not
applicable. Each SV has been divided in three segments in the cranio-spinal axis.
# The number of ISV could range from 1 (one proximal third of on ISV only) to 6 (two whole ISV). The logistic regression test has been used for acute toxicity. The Cox
model has been used for late toxicity. For significant p-values (p�0.05), hazard ratios (HR) with 95% confidence intervals (CI) are given.
https://doi.org/10.1371/journal.pone.0210514.t008
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Our study contains several limitations. The follow-up is short (26 months), explained by
the recent generalization and accessibility of MRI at initial staging. Urinary toxicity must be
therefore interpreted with precaution, knowing the possibility of late events. Moreover the
analysis is retrospective, justifying the analysis of high grades of toxicity only (grade� 2).
Finally, a very small proportion of patients (8%) had a SV biopsy, confirming the ISV. Our
Table 9. Multivariate analysis testing the impact of all parameters on grade� 2 toxicity in the whole series and for patients without lymph node involvement on
MRI.
Endpoints Whole series Patients without lymph node involvement
Parameters p value HR (95%
CI)
AUC/C-
index
Parameters p
value
HR (95%
CI)
AUC/C-
index
Acute
toxicity
Urinary toxicity
grade� 2
Cardiovascular disease 0.018 2.45 (1.16–
5.15)
0.57 Cardiovascular disease 0.035 2.33 (1.06–
5.13)
0.58
Digestive toxicity
grade� 2
Dose prescribed to non-involved
SV
<0.001 1.09 (1.04–
1.13)
0.73 Dose prescribed to non-
involved SV
0.018 1.06 (1.01–
1.12)
0.69
Late
toxicity
Urinary toxicity
grade� 2
ADT duration 0.016 0.98 (0.96–
0.99)
0.55 ADT duration 0.013 0.97 (0.96–
0.99)
0.56
Digestive toxicity
grade� 2
Age 0.010 1.09 (1.02–
1.16)
0.78 Age 0.020 1.10 (1.02–
1.20)
0.84
Dose prescribed to non-involved
pelvic lymph node
0.004 1.12 (1.04–
1.22)
Arterial hypertension 0.040 3.33 (1.06–
10.50)
Dose prescribed to pelvic
lymph node
0.026 1.21 (1.02–
1.43)
ADT: androgen deprivation therapy; AUC: Area under the ROC curve. A logistic regression test has been used for acute toxicity and a cox model for late toxicity. For
significant p-values (p�0.05), hazard ratios (HR) with 95% confidence intervals (CI) are given. The predictive capabilities of the logistic regression and Cox models
were estimated using the area under the receiver operating characteristic (ROC) curve (AUC) and the C-index, respectively.
https://doi.org/10.1371/journal.pone.0210514.t009
Fig 4. Impact of pelvic node dose on late digestive toxicity (grade� 2). The p value has been calculated from the logrank test.
https://doi.org/10.1371/journal.pone.0210514.g004
Radiotherapy for prostate cancer with seminal vesicle involvement
PLOS ONE | https://doi.org/10.1371/journal.pone.0210514 January 25, 2019 17 / 23
Table 10. Review of the literature reporting treatment for T3b prostate cancer.
TREATMENT STUDIES Nb PATIENTS AND TUMOR
CHARCTERISTICS
ADJUVANT
TREATMENT
CARCINOLOGICAL RESULTS
Age
(Y)
PSA
(ng/
mL)
Gleason
score (%)
N1
(%)
ADT
(%)
RT
(%)
ADT
and
RT (%)
Follow-
up
(months)
DFS (%) MFS (%) CSS (%) OS (%)
Surgery Moschini [37] 3279 65 22 6: 17%
7: 46%
8–10:
37%
38 36 14 8 148 5-Y: 50
10-Y: 36
- 5-Y: 94
10-Y: 86
5-Y: 90
10-Y: 73
Hubanks [8] 1132 66 10 6: 27%
7: 49%
8–10:
24%
No 30 12 - 127 10-Y: 41 10-Y: 81 5-Y: 96
10-Y: 89
10-Y: 59
Pierorazio [9] 989 60 10 6 : 10%
7 : 55%
8–10 :
35%
25 28 5 - 160 5-Y: 38
10-Y : 25
5-Y: 83
10-Y: 70
5-Y: 94
10-Y: 81
-
Secin [10] 387 62 11 6–7: 83%
8–10:
17%
24 No No No 68 5-Y: 38 - 5-Y: 96
10-Y: 85
-
Siddiqui [11] 382 66 4 6: 27%
7: 48%
8–10:
25%
No 50 No No 120 5-Y: 70 with
ADT and 32
without
10-Y:
60 with and 16
without
5-Y: 93
with ADT
and 88
without
10-Y: 88
with ADT
and 78
without
5-Y: 98
with ADT
and 97
without
10-year:
94 with
ADT and
87 without
10-Y: 75%
with ADT
and 69%
without
Jang [12] 350 67 16 6–7: 37%
8–10:
63%
20 No No No 69 5-Y: 21 - - -
Bastide [13] 199 64 13 6: 11%
7: 75%
8–10:
25%
No 38, 46 25 60 5-Y: 48 - - 5-Y: 93
Pagano [38] 180 64 9 6–7: 50%
8: 20%
9–10:
30%
12 No No No 27 5-Y: 60 - - -
SWOG 8794
[39]
139 65 - - No No 51 No 146 5-Y: 49
10-Y: 22
5-Y: 74 - 5-Y: 86
10-Y: 61
Salomon [40] 137 64 17 6–7: 63%
8–10:
37%
No No No No 59 5-Y : 34
10-Y : 10
- - -
Freedland [41] 135 63 18 6: 25%
7: 45%
8–10:
30%
No No No No 44 5-Y : 36 - - -
(Continued)
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patients are likely, however, to have true pathological ISV, as suggested by the high specificity
of MRI for ISV [3]. The presence of lymph nodes on MRI was, nevertheless, a poor prognostic
factor.
In conclusion, IMRT combined with IGRT allows delivery of a high curative dose (� 70
Gy) to the ISV in the majority of cases, while rarely exceeding dose-constraint recommenda-
tions at the planning. Acute and late-grade� 2 digestive toxicity appears moderate
(rates < 15%), whereas urinary toxicity is higher (> 30%) and slightly increased, compared to
the reported toxicity after high dose delivered to the prostate only. Local control is high (94%),
and the main pattern of recurrence is metastasis, mostly related to the lymph node involve-
ment on MRI at diagnosis.
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Table 10. (Continued)
TREATMENT STUDIES Nb PATIENTS AND TUMOR
CHARCTERISTICS
ADJUVANT
TREATMENT
CARCINOLOGICAL RESULTS
Age
(Y)
PSA
(ng/
mL)
Gleason
score (%)
N1
(%)
ADT
(%)
RT
(%)
ADT
and
RT (%)
Follow-
up
(months)
DFS (%) MFS (%) CSS (%) OS (%)
EBRT + BT Koutrouvelis�
[51]
37 68 20 6: 19%
7 : 56%
8 : 25%
No No - - 24 2-Y: 79 - - -
Stone [47] 52 70 - 6: 25%
7 : 44%
8–10 :
31%
No All - - 56 5-Y: 70
10-Y: 64
- 10-Y: 91 10-Y: 83
Rades [48] 38 - - 6–7: 73%
8–10 :
27%
No All, 5
months
- - 37 3-Y: 79 and 57
with and
without dose
escalation in
SV
- - -
Tsamura [49] 80 72 47 6: 5%
7: 42%
8: 24%
9–10:
29%
No All, 36
months
- - 74 5-Y: 82
10-Y: 64
- 5-Y: 95
10-Y: 91
5-Y: 88
10-Y: 84
Stone [50] 53 66 - 6: 19%
7 : 36%
8–10 :
45%
No All - - 109 10-Y: 61 10-Y: 78 10-Y: 77 -
EBRT only Our series 276 69 27 6: 7%
7: 51%
8–10:
42%
26% All - - 36 5-Y: 66 - 5-Y: 90 5-Y: 79
Selected surgery studies comprise a minimum of 100 patients, with Gleason score and pelvic lymph node involvement analyzed on pathological examination. Mean
values are given. Nb: number of patients; Y: year; N1: pelvic lymph node involvement on pathological examination in case of surgery or on imaging (CT or MRI) in case
of radiotherapy; ADT: androgen deprivation therapy; EBRT: external beam radiotherapy; BT: brachytherapy; DFS: disease-free survival; MFS: metastasis-free survival;
CSS: cause-specific survival; OS: overall survival.
�BT only.
https://doi.org/10.1371/journal.pone.0210514.t010
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